By Fineline Cube 
Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. The integration of Prothya with Accord B.V. marks a major expansion of the company’s plasma‑therapy business and strengthens its capacity to deliver plasma‑derived medicinal products (PDMPs) worldwide.
Strategic Rationale
- European Expertise Meets Global Scale – Prothya’s long‑standing plasma fractionation operations in Amsterdam and Brussels, along with its collection centers across Hungary, provide a proven European foothold. Combined with Intas’ large‑scale fractionation infrastructure in India, the merged entity will accelerate development and supply of essential PDMPs.
- Supply‑Chain Synergy – The acquisition enables streamlined sourcing, processing, and distribution of plasma‑derived products, enhancing resilience and reducing time‑to‑market for critical therapies.
- Geographic Expansion – The integrated company will serve patients across multiple regions, leveraging Prothya’s established European network and Intas’ reach in Asia and the Americas.
Key Operational Highlights
| Asset | Location | Role |
|---|---|---|
| Prothya Biosolutions | Amsterdam, Brussels, Hungary | Plasma fractionation, collection, and distribution |
| Intas Fractionation Facilities | India | Large‑scale production, quality control, and logistics |
- Plasma‑Derived Medicinal Products (PDMPs) – Includes albumin, immunoglobulins, and clotting factor concentrates.
- Regulatory Alignment – Both entities have compliant GMP facilities and meet EMA, FDA, and WHO standards.
Future Outlook
Accord Plasma plans to:
- Integrate Operations – Consolidate manufacturing processes and quality systems to achieve cost efficiencies.
- Accelerate Product Development – Leverage combined R&D capabilities to bring new PDMP indications to market.
- Expand Market Penetration – Utilize the expanded distribution network to increase access for patients in underserved regions.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech